atacand plus mite 8 mg / 12.5 mg
cheplapharm arzneimittel gmbh - kandesartancileksetil / hydroklortiazid - tablett - 8 mg / 12.5 mg
atacand plus 32 mg / 12.5 mg
cheplapharm arzneimittel gmbh - kandesartancileksetil / hydroklortiazid - tablett - 32 mg / 12.5 mg
entocort 3 mg
tillotts pharma gmbh - budesonid - depotkapsel, hard - 3 mg
plendil 5 mg
glenwood gmbh - felodipin - depottablett - 5 mg
plendil 10 mg
glenwood gmbh - felodipin - depottablett - 10 mg
symbicort 160 mikrog/ dose / 4.5 mikrog/ dose
astrazeneca - budesonid / formoterolfumaratdihydrat - inhalasjonsaerosol, suspensjon - 160 mikrog/ dose / 4.5 mikrog/ dose
symbicort mite turbuhaler 80 mikrog/ dose / 4.5 mikrog/ dose
astrazeneca - budesonid / formoterolfumaratdihydrat - inhalasjonspulver - 80 mikrog/ dose / 4.5 mikrog/ dose
symbicort turbuhaler 160 mikrog/ dose / 4.5 mikrog/ dose
astrazeneca - budesonid / formoterolfumaratdihydrat - inhalasjonspulver - 160 mikrog/ dose / 4.5 mikrog/ dose
symbicort forte turbuhaler 320 mikrog/ dose / 9 mikrog/ dose
astrazeneca - budesonid / formoterolfumaratdihydrat - inhalasjonspulver - 320 mikrog/ dose / 9 mikrog/ dose
beyfortus
astrazeneca ab - nirsevimab - immune sera og immunglobuliner, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.